A new article in the journal JAMA Oncology has again suggested that the use of 5α-reductase inhibitors (5-ARIs) like finasteride/Proscar and dutasteride/Avodart is not, in fact, associated with any significant risk for clinically significant prostate cancer let alone risk for prostate cancer-specific mortality. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, 5α-reductase inhibitor, mortality, risk | 4 Comments »
A new review of the available literature has concluded that, despite the fact that “prostate cancer is an ideal target for prevention,” there is in fact “no suitable evidence to recommend using any specific nutritional supplement or diet to prevent prostate cancer” at the present time. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, 5α-reductase inhibitor, diet, nutrition, Prevention, supplement | 1 Comment »
The “New” Prostate Cancer InfoLink is delighted to see Dr. Pazdur and colleagues from the U.S. Food & Drug Administration (FDA) present their reasoning for non-approval of the 5α-reductase inhibitors (5-ARIs) dutasteride and finasteride for prevention of prostate cancer in a new article in the New England Journal of Medicine. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Prevention, Risk | Tagged: 5-ARI, 5α-reductase inhibitor, FDA, Prevention | 11 Comments »
The “New” Prostate Cancer InfoLink has long argued that the potential of 5α-reductase inhibition (using finasteride and dutasteride) to prevent prostate cancer is under-appreciated and under-utilized. However, we also acknowledge a lack of good data to identify those patients for whom the benefits of prevention may outweigh the risks associated with the side effects of such treatment. … READ MORE …
Filed under: Management, Prevention | Tagged: 5α-reductase inhibitor, dutasteride, finasteride, Prevention | 2 Comments »
In August this year, Vis and Schröder published the first of two summary reviews on the key targets of hormonal treatment of prostate cancer. The second of these two key reviews has now appeared in the November issue of BJU International. … READ MORE …
Filed under: Management, Treatment, Uncategorized | Tagged: 5-ARIs, 5α-reductase inhibitor | 11 Comments »
In today’s news report we touch on papers that address:
Filed under: Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: 5α-reductase inhibitor, focal therapy, genome, marker, Prevention, risk, selenium, SNP, targeted | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 